MED17

Across TCGA pan-cancer cohorts, MED17 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MED17’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where MED17 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MED17 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

LUAD, HNSC, and PDAC are the cancer types where MED17 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MED17 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	II,III,IV	+0.185	<.001	7	view →
HNSC	All	III,IV	−0.242	.003	6	view →
PDAC	All	All	−0.527	<.001	5	view →
CCRCC	Male	All	+0.209	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MED17–LUAD

Open the LUAD breakdown →